银安方与安慰剂颗粒治疗常染色体显性多囊肾病III-IV期慢性肾脏病患者的双盲安慰剂对照随机临床试验研究方案
这是一项多中心前瞻性双盲随机对照试验的研究方案,计划纳入72例常染色体显性多囊肾病合并慢性肾脏病III-IV期且中医辨证为脾肾亏虚兼血瘀证的患者,按1:1随机接受银安方联合常规治疗或安慰剂联合常规治疗24周,并随访24周,主要结局为估算肾小球滤过率。
要点
- 银安方源自中成药,拟作为常染色体显性多囊肾病合并慢性肾脏病III-IV期脾肾亏虚兼血瘀证患者的补充药物。
- 试验计划纳入72例,1:1随机分配至银安方联合常规治疗组或安慰剂联合常规治疗组,干预24周后随访24周。
- 主要结局为估算肾小球滤过率,次要结局包括总肾脏体积、血肌酐、血尿素氮、中医症状和疼痛的变化。
核心结论
- 本研究将是首个安慰剂对照随机对照试验,评估银安方联合常规治疗对常染色体显性多囊肾病合并慢性肾脏病III-IV期脾肾亏虚兼血瘀证患者估算肾小球滤过率、总肾脏体积、血肌酐和血尿素氮的影响,以及能否缓解中医临床症状、减少多囊肾病相关疼痛和降低不良事件频率。
- 试验结果可能为临床医生提供循证推荐。
研究设计与样本
- 多中心前瞻性双盲随机对照试验,计划总样本量72例,按1:1均衡分配。
- 试验组为银安方联合常规治疗,对照组为安慰剂联合常规治疗,疗程24周,治疗结束后再随访24周。
- 主要结局为估算肾小球滤过率;次要结局为总肾脏体积、血肌酐、血尿素氮、中医症状和疼痛的变化;整个试验期间监测不良事件。
临床怎么用
- 作者认为试验结果可能为临床医生提供循证推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common potentially life-threatening inherited kidney diseases. It is the fourth most common cause of end-stage renal disease requiring renal replacement therapy. There are few management options for controlling disease progression. Hence, identification of alternative treatments for patients is important. The Chinese herbal yinang formulation (YNF), which is derived from a Chinese patent medicine, appears to have a satisfactory effect in treating ADPKD. Because a considerable proportion of ADPKD patients presenting with chronic kidney disease (CKD) stages III-IV are diagnosed with the spleen, kidney deficiency, and blood stasis syndrome according to the diagnostic criteria of traditional Chinese medicine (TCM), we hypothesize that YNF may be a complementary drug for ADPKD patients with the corresponding syndrome. Therefore, we have designed a strict clinical trial to evaluate the safety and efficacy of YNF for ADPKD patients with CKD stages III-IV exhibiting the TCM syndrome of spleen, kidney deficiency, and blood stasis. METHODS/DESIGN: This is a multi-center prospective double-blind randomized controlled trial. The total target sample size is planned to be 72 participants, with a balanced treatment allocation (1:1). The experimental intervention will be YNF plus conventional therapy and the control intervention will be a placebo plus conventional therapy for 24 weeks. An additional 24 weeks of follow-up will be conducted after treatment completion. The primary outcome will be the estimated glomerular filtration rate (eGFR). Changes in total kidney volume (TKV), serum creatinine (Scr), blood urea nitrogen (BUN), TCM symptoms, and pain will be the secondary outcomes. Adverse events (AEs) will be monitored throughout the trial. DISCUSSION: This study will be the first placebo-controlled randomized controlled trial to assess whether YNF plus conventional therapy has a beneficial effect on eGFR, TKV, Scr, and BUN, and whether it can alleviate TCM clinical symptoms, reduce ADPKD-related pain, and reduce the frequency of AEs for ADPKD patients with CKD stages III-IV with the spleen, kidney deficiency, and blood stasis syndrome. The results of this trial may provide an evidence-based recommendation for clinicians. TRIAL REGISTRATION: Chinese Clinical Trials Register, ChiCTR-INR-16009914 . Registered on 18 November 2016.
引用
- Gan J, Wu Y, Gong X, et al. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial. Trials. 2019. PMID: 31391092. doi:10.1186/s13063-019-3563-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。